Gene signatures for cancer prognosis

A method for treating prostate cancer, lung cancer, bladder cancer, brain cancer or breast cancer in a patient in need, the method comprising:

• measuring in a cancer sample obtained from the patient expression levels of a panel of genes comprising at least three genes of a set of genes comprising ASF1B, ASPM, BIRC5, BUB1B, C18orf24, CDC2, CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXM1, KIAA0101, KIF11, KIF20A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1, and TOP2A;
• calculating a test prognostic score combining the expression levels with a clinical variable of the patient;
• prognosing the patient as having an increased likelihood of cancer recurrence or cancer-specific death based at least in part on the test prognostic score exceeding a reference prognostic score;
• and
• administering one or more of hormonal therapy, chemotherapy, radiation therapy or surgery to the patient prognosed as having an increased likelihood of cancer recurrence or cancer-specific death.

A method for treating prostate cancer, lung cancer, bladder cancer, brain cancer or breast cancer in a patient in need, the method comprising:

• measuring in a cancer sample obtained from the patient expression levels of a panel of genes comprising at least three genes of a set comprising ASF1B, ASPM, BIRC5, BUB1B, C18orf24, CDC2, CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXM1, KIAA0101, KIF11, KIF20A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1, and TOP2A;
• calculating a test prognostic score combining the expression levels with a clinical variable of the patient;
• prognosing the patient as having no increased likelihood of cancer recurrence or cancer-specific death based at least in part on the test prognostic not exceeding a reference prognostic score;
• administering active surveillance to the cancer patient prognosed as having no increased likelihood of cancer recurrence or cancer-specific death;
• and
• administering one or more of hormonal therapy, chemotherapy, radiation therapy or surgery to the patient based on the presence of cancer symptoms and/or signs of accelerated cancer growth in the patient who was administered active surveillance.